Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the...
Read More Details
Finally We wish PressBee provided you with enough information of ( GlycoNex to Present Preclinical Data on GNX1021 at AACR 2025 )
Also on site :
- Judge blocks immigrants’ deportation to South Sudan one day after Supreme Court clears the way
- Will Chicago have Fourth of July fireworks? What to know about Navy Pier schedule
- Legendary Hard Rock Band Teases Big Event With ‘Probably the Greatest Photo in Rock/ Metal History’